Active, not recruitingPhase 2NCT05186753
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Studying Indolent systemic mastocytosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cogent Biosciences, Inc.
- Principal Investigator
- Rachael Easton, MD, PhD, FNP-BCCogent Biosciences
- Intervention
- Bezuclastinib Tablets (Formulation A)(drug)
- Enrollment
- 237 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2030
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Mayo Clinic Arizona, Phoenix, Arizona, United States
- One of a Kind Clinical Research Center, Scottsdale, Arizona, United States
- Modena Allergy and Asthma Clinical, La Jolla, California, United States
- Innovative Research of West Florida, Clearwater, Florida, United States
- Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
- University of South Florida, Tampa, Florida, United States
- Emory University, Atlanta, Georgia, United States
- Rush University, Chicago, Illinois, United States
- Walter Reed National Military Medical Center, Bethesda, Maryland, United States
- Allervie Clinical Research, Glenn Dale, Maryland, United States
- Institute for Asthma and Allergy, Wheaton, Maryland, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05186753 on ClinicalTrials.govOther trials for Indolent systemic mastocytosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07255638A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in GermanyBlueprint Medicines Corporation
- RECRUITINGPHASE2, PHASE3NCT04910685(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic MastocytosisBlueprint Medicines Corporation
- RECRUITINGPHASE2NCT04655118Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic MastocytosisTelios Pharma, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT03731260(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic MastocytosisBlueprint Medicines Corporation